

BEST AVAILABLE COPY**Docket No.: PHRM0002-105/PC30125A**
PATENT**Appl. Number: 10/523,893**
Filed: 09/06/2005**REMARKS****Status of the Claims****RECEIVED**
CENTRAL FAX CENTER**FEB 09 2007**

Claims 1-48 are pending in the application.

Claims 1-48 are subject to a restriction requirement.

By way of this amendment, claims 5-14 and 34-48 have been canceled, claims 21, 24 and 33 have been amended and new claims 49-60 have been added.

Upon entry of this amendment, claims 1-4, 15-33 and 49-60 will be pending.

Summary of the Amendment

Claims 5-14 and 34-48 have been canceled as being directed to a non-elected invention.

Claims 21, 24 and 33 have been amended to correct obvious grammatical errors.

New claims 49-60 have been added to more specifically claim embodiments of the invention. Support for the new claims is found throughout the specification and claims as originally filed. No new matter has been added.

Restriction Requirement and Election of Species

Claims 1-48 have been subject to a restriction requirement wherein Applicants have been required to elect one invention from the following groups:

Group I, claims 1-4 and 15-33, drawn to a binding assay employing a DmGPCR and DmGPCR binding partner;

Group II, claims 5-9 and 34-43, only in so far as they relate to a method of controlling insects by administering a DmGPCR binding partner;

Group III, claims 5-9 and 34-43, only in so far as they relate to a method of controlling insects by administering a DmGPCR polynucleotide modulator;

Group IV, claims 5-9 and 34-43, only in so far as they relate to a method of controlling insects by administering a DmGPCR polypeptide modulator; and

RECEIVED
CENTRAL FAX CENTER

BEST AVAILABLE COPY

Docket No.: PHRM0002-105/PC30125A
PATENT

FEB 09 2007

Appl. Number: 10/523,893

Filed: 09/06/2005

Group V, claims 10-14 and 44-48, drawn to a method of treating a subject by administering a DmGPCR binding partner.

Applicants elect Group I, claims 1-4 and 15-33, drawn to a binding assay employing a DmGPCR and DmGPCR binding partner.

Applicants are further required to elect a species for examination with respect to "purified and isolated DmGPCR polypeptides" and "DmGPCR binding partners."

Applicants elect that initial examination be directed to the DmGPCR polypeptide, which is DmGPCR 7 and the DmGPCR 7 binding partner LK-1.

Claims 15, 19-21, 28-30 and 49-60 read on the elected species.

Conclusion

Examination of the claims and their passage to allowance are respectfully requested. An early Notice of Allowance is therefore earnestly solicited. Applicants invite the Examiner to contact the undersigned attorney at 215.665.5592 to clarify any unresolved issues raised by this response.

As indicated on the transmittal accompanying this response, the Commissioner is hereby authorized to charge any debit or credit any overpayment to Deposit Account No. 50-1275.

Respectfully submitted,



Mark DeLuca
Registration No. 33,229

Date: February 9, 2007
COZEN O'CONNOR, P.C.
1900 Market Street
Philadelphia, PA 19103-3508
Telephone: 215.665.5592
Facsimile: 215.701.2100